Parkinson’s Disease Study
If you or a loved one has been diagnosed with early-stage Parkinson’s Disease, a clinical trial might be able to help. This trial is testing a drug against brain inflammation. We are enrolling people who have Parkinson’s disease with symptoms beginning within the last two years.
Who’s Included?
Adults
40–85
Drug & Formulation
BHV-8000
Once-Daily Oral Tablet
Possibility of Placebo
Parkinson’s disease is a condition that affects the way your body moves. It happens when certain nerve cells in the brain stop working properly and don’t produce enough dopamine, a chemical that helps control movement. This can lead to symptoms like shaking (tremors), stiffness, slow movements, and trouble with balance. Some people may also experience changes in mood, sleep, or thinking as the disease progresses. While there is currently no cure and no approved interventions that can slow the progression of Parkinson’s disease, there are treatments including medication, exercise, and therapy that can help manage symptoms and improve quality of life.
Visit ClinicalTrials.gov for detailed information on the study.
- Be 40-85 years of age at the time of signing the informed consent form
- Have a documented diagnosis of Parkinson’s disease that started within 2 years of the first (screening) study visit.
- Not currently taking any medications for Parkinson’s disease.
- Have a medical history of a movement disorder other than Parkinson’s disease
- Have a recent history of serious cardiovascular event (heart attack or stroke) or infection
- Be a current smoker or someone who smoked within the last 6 months.
Frequently Asked Questions
About 550 people will participate in this study.
The study is being conducted on behalf of Biohaven by multiple sites (research clinics or hospitals) across the United States and around the world with trained and qualified medical specialists.
Visit See If You Qualify page to see if you qualify and find a clinic near you.